Table 42Study information table for trials comparing quetiapine with placebo

Quetiapine (50 mg) versus placeboQuetiapine (150 mg) versus placeboQuetiapine (300 mg) versus placeboQuetiapine (flexible dose) versus placebo
No. trials
(total participants)
2 RCTs
(907)
3 RCTs
(1345)
2 RCTs
(898)
1 RCT
(450)
Study ID
ASTRAZENECA 2008
N/% of female
  1. 873/65%
  2. Not reported
(1) 873/65%
(2)–(3) Not reported
(1)–(2) Not reported450/57%
Mean age (years) (see Appendix 15d for data for individual studies)41403970
Diagnosis(1)-(2) GAD by DSM-IV(1)-(3) GAD by DSM-IV(1)-(2) GAD by DSM-IVGAD by DSM-IV
Baseline severityNot reportedNot reportedNot reportedNot reported
Treatment length8 weeks8 weeks8 weeks9 weeks
Follow-upEnd of treatmentEnd of treatmentEnd of treatmentEnd of treatment

From: 8, PHARMACOLOGICAL AND PHYSICAL INTERVENTIONS

Cover of Generalised Anxiety Disorder in Adults
Generalised Anxiety Disorder in Adults: Management in Primary, Secondary and Community Care.
NICE Clinical Guidelines, No. 113.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2011.
Copyright © 2011, The British Psychological Society & The Royal College of Psychiatrists.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.